| Dr Christopher Bryant Lynch, MD | |
|
469 W Main St, Branford, CT 06405-3400 | |
| (203) 865-6784 | |
| (203) 865-6788 |
| Full Name | Dr Christopher Bryant Lynch |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 26 Years |
| Location | 469 W Main St, Branford, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952307456 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 042192 (Connecticut) | Secondary |
| 207XS0114X | Orthopaedic Surgery - Adult Reconstructive Orthopaedic Surgery | 042192 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Midstate Medical Center | Meriden, CT | Hospital |
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Connecticut Orthopaedic Specialists Pc | 7315850039 | 154 |
| Omni Physical And Aquatic Therapy Center, Inc | 2769419514 | 14 |
| Rehabilitation Associates Inc | 8022905322 | 297 |
News Archive
HemoBioTech announced today the issuance of a new patent US 7,759,306 B2, Methods of Treating Acute Blood Loss. HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.
It is widely accepted that higher levels of body fat increase the risk of developing breast cancer, as well as other cancers.
A DNA-sensing enzyme forms droplets that act as tiny bioreactors creating molecules to stimulate innate immunity – the body's first response to infection, UT Southwestern researchers report. The work, reported today in the journal Science, could lead to novel treatments for infections, autoimmune disease, and cancer.
A cancer scientist from Johns Hopkins has convinced an international group of colleagues to delay their race to find new cancer biomarkers and instead begin a 7,000-hour slog through a compendium of 50,000 scientific articles already published to assemble, decode and analyze the molecules that might herald the furtive presence of pancreatic cancer.
› Verified 6 days ago
| Entity Name | Connecticut Orthopaedic Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235181389 PECOS PAC ID: 7315850039 Enrollment ID: O20031110000220 |
News Archive
HemoBioTech announced today the issuance of a new patent US 7,759,306 B2, Methods of Treating Acute Blood Loss. HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.
It is widely accepted that higher levels of body fat increase the risk of developing breast cancer, as well as other cancers.
A DNA-sensing enzyme forms droplets that act as tiny bioreactors creating molecules to stimulate innate immunity – the body's first response to infection, UT Southwestern researchers report. The work, reported today in the journal Science, could lead to novel treatments for infections, autoimmune disease, and cancer.
A cancer scientist from Johns Hopkins has convinced an international group of colleagues to delay their race to find new cancer biomarkers and instead begin a 7,000-hour slog through a compendium of 50,000 scientific articles already published to assemble, decode and analyze the molecules that might herald the furtive presence of pancreatic cancer.
› Verified 6 days ago
| Entity Name | Northeast Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043278351 PECOS PAC ID: 1254233836 Enrollment ID: O20040123000522 |
News Archive
HemoBioTech announced today the issuance of a new patent US 7,759,306 B2, Methods of Treating Acute Blood Loss. HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.
It is widely accepted that higher levels of body fat increase the risk of developing breast cancer, as well as other cancers.
A DNA-sensing enzyme forms droplets that act as tiny bioreactors creating molecules to stimulate innate immunity – the body's first response to infection, UT Southwestern researchers report. The work, reported today in the journal Science, could lead to novel treatments for infections, autoimmune disease, and cancer.
A cancer scientist from Johns Hopkins has convinced an international group of colleagues to delay their race to find new cancer biomarkers and instead begin a 7,000-hour slog through a compendium of 50,000 scientific articles already published to assemble, decode and analyze the molecules that might herald the furtive presence of pancreatic cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Bryant Lynch, MD 9 Washington Ave Fl 1a, Hamden, CT 06518-3267 Ph: (203) 865-6784 | Dr Christopher Bryant Lynch, MD 469 W Main St, Branford, CT 06405-3400 Ph: (203) 865-6784 |
News Archive
HemoBioTech announced today the issuance of a new patent US 7,759,306 B2, Methods of Treating Acute Blood Loss. HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.
It is widely accepted that higher levels of body fat increase the risk of developing breast cancer, as well as other cancers.
A DNA-sensing enzyme forms droplets that act as tiny bioreactors creating molecules to stimulate innate immunity – the body's first response to infection, UT Southwestern researchers report. The work, reported today in the journal Science, could lead to novel treatments for infections, autoimmune disease, and cancer.
A cancer scientist from Johns Hopkins has convinced an international group of colleagues to delay their race to find new cancer biomarkers and instead begin a 7,000-hour slog through a compendium of 50,000 scientific articles already published to assemble, decode and analyze the molecules that might herald the furtive presence of pancreatic cancer.
› Verified 6 days ago
Philip A Minotti, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 84 N Main St, Branford, CT 06405 Phone: 203-407-3544 Fax: 203-466-8596 | |
Peter A. Deluca, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 84 N Main St, Branford, CT 06405 Phone: 203-407-3570 Fax: 203-466-8593 |